Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederick Lansigan

Showing results (51-60 of 87) with videos related to

Pageof 9
Sort By:
The American Journal of Occupational Therapy : Official Publication of the American Occupational Therapy Association|September 5, 2019
Health Through Activity: Initial Evaluation of an In-Home Intervention for Older Adults With CancerKathleen Doyle Lyons, Martha L Bruce, Jay G Hull, et al.
Blood Advances|September 2, 2022
Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphomaJeremy S Abramson, Elizabeth Bengston, Robert Redd, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 14, 2020
Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort StudyFrederick Lansigan, Steven M Horwitz, Lauren C Pinter-Brown, et al.
British Journal of Haematology|December 22, 2015
Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective studyJorge J Castillo, Shirley D'Sa, Michael P Lunn, et al.
British Journal of Haematology|March 13, 2018
Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphomaJorge J Castillo, Thomas Guerrero-Garcia, Francesco Baldini, et al.
Future Oncology (London, England)|April 7, 2020
ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1Grzegorz S Nowakowski, Jun Zhu, Qingyuan Zhang, et al.
Frontiers in Oncology|November 12, 2021
Oncogenic Integration of Nucleotide Metabolism <i>via</i> Fatty Acid Synthase in Non-Hodgkin LymphomaDashnamoorthy Ravi, Afshin Beheshti, Nasséra Abermil, et al.
Blood and Lymphatic Cancer : Targets and Therapy|September 18, 2020
The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial TherapyChaitra Ujjani, Anthony Mato, Brian T Hill, et al.
The Lancet. Haematology|February 25, 2021
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trialJeff P Sharman, Danielle M Brander, Anthony R Mato, et al.
Leukemia & Lymphoma|October 3, 2018
Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of originTalha Badar, Mehdi Hamadani, Veronika Bachanova, et al.
Pageof 9

Showing results (51-60 of 87) with videos related to

Sort By:
Pageof 9
The American Journal of Occupational Therapy : Official Publication of the American Occupational Therapy Association|September 5, 2019
Health Through Activity: Initial Evaluation of an In-Home Intervention for Older Adults With CancerKathleen Doyle Lyons, Martha L Bruce, Jay G Hull, et al.
Blood Advances|September 2, 2022
Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphomaJeremy S Abramson, Elizabeth Bengston, Robert Redd, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 14, 2020
Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort StudyFrederick Lansigan, Steven M Horwitz, Lauren C Pinter-Brown, et al.
British Journal of Haematology|December 22, 2015
Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective studyJorge J Castillo, Shirley D'Sa, Michael P Lunn, et al.
British Journal of Haematology|March 13, 2018
Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphomaJorge J Castillo, Thomas Guerrero-Garcia, Francesco Baldini, et al.
Future Oncology (London, England)|April 7, 2020
ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1Grzegorz S Nowakowski, Jun Zhu, Qingyuan Zhang, et al.
Frontiers in Oncology|November 12, 2021
Oncogenic Integration of Nucleotide Metabolism <i>via</i> Fatty Acid Synthase in Non-Hodgkin LymphomaDashnamoorthy Ravi, Afshin Beheshti, Nasséra Abermil, et al.
Blood and Lymphatic Cancer : Targets and Therapy|September 18, 2020
The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial TherapyChaitra Ujjani, Anthony Mato, Brian T Hill, et al.
The Lancet. Haematology|February 25, 2021
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trialJeff P Sharman, Danielle M Brander, Anthony R Mato, et al.
Leukemia & Lymphoma|October 3, 2018
Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of originTalha Badar, Mehdi Hamadani, Veronika Bachanova, et al.
Pageof 9